INT266746

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 3.44
Pain Relevance 5.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 467 99.88 Very High Very High Very High
abatacept 238 99.40 Very High Very High Very High
methotrexate 368 98.80 Very High Very High Very High
Arthritis 97 94.96 High High
Etanercept 207 93.28 High High
Pain 26 89.36 High High
psoriasis 10 87.56 High High
Adalimumab 223 85.08 High High
antagonist 44 61.64 Quite High
Infliximab 100 56.32 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 474 99.88 Very High Very High Very High
Seronegative Spondarthritis 65 94.96 High High
Disease 203 89.88 High High
Psoriasis 12 87.56 High High
Pain 25 78.56 Quite High
Nail Diseases 4 74.68 Quite High
Toxicity 8 53.20 Quite High
Juvenile Chronic Polyarthritis 2 51.60 Quite High
Low Back Pain 66 50.00 Quite Low
Infection 63 48.76 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Data from 57 patients evaluated for efficacy showed that 77%, 47%, and 23% of patients met ACR20, ACR50, and ACR70 criteria, respectively, after 3 years of therapy [22].
ACR70 Binding (met) of
1) Confidence 0.23 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.40 Pain Relevance 0.66
Data from 57 patients evaluated for efficacy showed that 77%, 47%, and 23% of patients met ACR20, ACR50, and ACR70 criteria, respectively, after 3 years of therapy [22].
ACR20 Binding (met) of
2) Confidence 0.23 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.39 Pain Relevance 0.66
Data from 57 patients evaluated for efficacy showed that 77%, 47%, and 23% of patients met ACR20, ACR50, and ACR70 criteria, respectively, after 3 years of therapy [22].
ACR50 Binding (met) of
3) Confidence 0.23 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.39 Pain Relevance 0.66
70 years old and had RA that met the American College of Rheumatology (ACR) classification criteria [14], with active RA for a duration ?
ACR Binding (met) of associated with rheumatoid arthritis
4) Confidence 0.13 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991028 Disease Relevance 0.60 Pain Relevance 0.48
Fig. 2ACR20, ACR50, and ACR70 response rates over time

ACR core components

ACR50 Binding (2ACR20) of
5) Confidence 0.09 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.08 Pain Relevance 0.26
No significant differences were found between abatacept 2 mg/kg and placebo, whereas improvement in ACR50 and ACR70 was significantly greater with abatacept 10 mg/kg (Table 5).
ACR50 Binding (improvement) of associated with abatacept
6) Confidence 0.04 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.24 Pain Relevance 0.90
No significant differences were found between abatacept 2 mg/kg and placebo, whereas improvement in ACR50 and ACR70 was significantly greater with abatacept 10 mg/kg (Table 5).
ACR70 Binding (improvement) of associated with abatacept
7) Confidence 0.04 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.24 Pain Relevance 0.91
All comparisons between GLM 50 or 100 mg with placebo, including HAQ scores, ACR50, ACR70, DAS28 responders, and PASI scores were significant at week 24 (P < 0.001 for all measures).26 The effect of GLM on physical function and self-reported productivity of patients with PsA, as well as on time lost from work by caregivers of patients, was also assessed.
ACR50 Binding (comparisons) of associated with arthritis
8) Confidence 0.03 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.55 Pain Relevance 0.36
All comparisons between GLM 50 or 100 mg with placebo, including HAQ scores, ACR50, ACR70, DAS28 responders, and PASI scores were significant at week 24 (P < 0.001 for all measures).26 The effect of GLM on physical function and self-reported productivity of patients with PsA, as well as on time lost from work by caregivers of patients, was also assessed.
ACR70 Binding (comparisons) of associated with arthritis
9) Confidence 0.03 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.55 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox